SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (14222)7/24/2000 10:27:19 PM
From: jnothpilot  Respond to of 17367
 
Wow, the last few months I have learned a lot about the drugs being discussed by you experts. I bought a lot of Xoma quite a while ago based on their pipeline, their technicals, and their management. However after lurking and watching you guys discuss their scientific and contractural achievements I now feel I made the right decision for the wrong reason. I visited XOMA and met their staff and was impressed but I had no idea all that Xoma had. Keep up the good work and welcome back Cacaito. It's good to hear your positive imput.



To: Bluegreen who wrote (14222)7/24/2000 11:13:31 PM
From: aknahow  Read Replies (1) | Respond to of 17367
 
I agree in principal but found Cacaito's post compelling. A combination product approved by the FDA would offer certain marketing advantages.

I still stand by the concept that it would take 10 years to develop a combination LLY/BAX/XOMA product. Of course nothing would stop any licensed physician from combining them assuming Neuprex is approved on its own. And who's to say that might not take longer than 10 years? <g>


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News